90Y-DOTA-CHS Microspheres for Live Radiomicrosphere Therapy: Preliminary In Vivo Lung Radiochemical Stability Studies

Authors

Alejandro Amor-Coarasa, Weill Cornell Medical College
Andrew Milera, Herbert Wertheim College of Medicine, Florida International UniversityFollow
Denny Carvajal, Department of Biomedical Engineering, Florida International University; Mount Sinai Medical Center
Seza Gulec, Herbert Wertheim College of Medicine and Department of Biomedical Engineering, Florida International University; Jackson North Medical CenterFollow
Anthony J. McGoron, Herbert Wetheim College of Medicine and Department of Biomedical Engineering, Florida International UniversityFollow

Date of this Version

2-3-2014

Document Type

Article

Abstract

Chitosan (CHS) is used to prepare microspheres of 31 ± 8 µm size. Surface modification with p-SCN-Bn-DOTA was performed. A maximum 90Y capacity was found to be 12.1 ± 4.4 µCi/particle. The best obtained labeling yield was 87.7 ± 0.6%. More than 90% in vitro stability was found. Particle in vitro degradation half-life in PBS was found to be greater than 21 days. In vivo studies with 90Y-DOTA-CHS showed more than 95% of the injected activity (decay corrected) in the lungs 24 hours after tail vein administration. 90Y-DOTA-CHS in vivo label stability was superior to resin microspheres. The addition of p-SCN-Bn-DOTA served as a radioprotectant for bone marrow as the 5% 90Y released, during the first 24 hours, was quickly eliminated via urine.

Comments

Originally published in Journal of Radiotherapy.

Identifier

FIDC001322

Recommended Citation

Alejandro Amor-Coarasa, Andrew Milera, Denny Carvajal, Seza Gulec, and Anthony J. McGoron, “90Y-DOTA-CHS Microspheres for Live Radiomicrosphere Therapy: Preliminary In Vivo Lung Radiochemical Stability Studies,” Journal of Radiotherapy, vol. 2014, Article ID 941072, 6 pages, 2014. doi:10.1155/2014/941072

Creative Commons License

This work is licensed under a Creative Commons Attribution 3.0 License.